<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0309234090
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        NOSTIFIX 0.5 mg TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CABERGOLINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        8
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        119.50
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jazeera Pharmaceutical Industries (JPI)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        G02CB03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        N04BC06
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>Nostifix contains the active ingredient cabergoline. This medicine belongs to a class of Medicines called &lsquo;dopamine agonists&rsquo;. Dopamine is produced naturally in the body and helps to transmit messages to the brain.</li><li>Nostifix is used to stop breast milk production (lactation) soon after childbirth, stillbirth, abortion or miscarriage. It can also be used if you do not want to continue to breast‐feed your baby once you have started.</li><li>Nostifix can also be used to treat other conditions caused by hormonal disturbance which can result in high levels of prolactin being produced. This includes lack of periods, infrequent and very light menstruation, periods in which ovulation does not occur and secretion of milk from your breast without breast-feeding. Also in conditions in which high levels&nbsp;of prolactin are due to unknown causes (idiopathic hyperprolactinaemia) or are caused by tumours of the pituitary gland in both men and women.</li><li>Cabergoline mimics the action of dopamine to reduce the production of prolactin in the blood. Prolactin is the hormone which stimulates the breast to produce milk.</li><li>Nostifix should only be used in adults. It is not suitable for children under the age of 16 years.</li><li>You must talk to a doctor or pharmacist if you do not feel better or if you feel worse.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Nostifix </strong></p><ul><li>If you are allergic to cabergoline, to other medicines called ergot alkaloids, (e.g. pergolide, bromocriptine, lisuride, ergotamine or ergometrine) or to any of the other ingredients of this medicine (listed in section 6)</li><li>If you have severe liver disease</li><li>If you have high blood pressure in pregnancy associated with swelling and protein in the urine (toxaemia of pregnancy)</li><li>If you are being treated with anti-psychotics or have a history of mental illness associated with child-birth (puerperal psychosis)</li><li>If you are pregnant or breast-feeding</li><li>If you will be treated with Nostifix for a long period and have stiff and inflamed heart valves (cardiac valvulopathy)</li><li>If you have had fibrotic reactions (scar tissue) affecting your abdomen, heart or lungs</li></ul><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor or pharmacist before taking Nostifix if you have or had any of the following conditions:</p><ul><li>Disease that involves the heart and blood vessels (cardiovascular disease)</li><li>Cold hands and feet (Raynaud&rsquo;s syndrome)</li><li>Gnawing pain in the abdomen when hungry (peptic ulcer) or bleeding from the stomach and intestines (gastrointestinal bleeding)</li><li>History of serious mental disease, particularly psychotic disorders</li><li>Reduced liver function</li><li>Kidney function abnormality or kidney disease</li><li>Increased blood pressure after giving birth</li><li>Fibrotic reactions (scar tissue) affecting your heart, lungs or abdomen. In case you are treated with Nostifix for a long period, your physician will check before starting treatment whether your heart, lungs and kidneys are in good condition. They will also have an echocardiogram (an ultrasound test of the heart) taken before treatment is started and at regular intervals during treatment. If fibrotic reactions occur treatment will have to be discontinued</li><li>Low blood pressure (postural hypotension) or you are taking any medicines to lower your blood pressure</li></ul><p>If you have just given birth you may be more at risk of certain conditions. These may include high blood pressure, heart attack, convulsion, stroke or mental health problems. Therefore, your doctor will need to check your blood pressure regularly during the treatment. Speak immediately to your doctor if you experience high blood pressure, chest pain or unusually severe or persistent headache (with or without vision problems).</p><p>Tell your doctor if you or your family/carer notices that you are developing urges or cravings to behave in ways that are unusual for you and you cannot resist the impulse, drive or temptation to carry out certain activities that could harm yourself or others. These are called impulse control disorders and can include behaviours such as addictive gambling, excessive eating or spending, an abnormally high sex drive or an increase in sexual thoughts or feelings. Your doctor may need to adjust or stop your dose.</p><p>It is recommended that women on long term treatment with Nostifix for hormonal disorders should have regular gynaecological exams including smear tests. Your doctor will continue to monitor your medical condition while you are taking Nostifix Tablets.</p><p><strong>Other medicines and Nostifix</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.</p><p>Some medicines can reduce the effectiveness of cabergoline, these include:</p><ul><li>Medicines used to treat mental illness (e.g. antipsychotic medicines like chlorpromazine, haloperidol)</li><li>Medicines for nausea and vomiting (e.g. domperidone, metoclopramide)</li><li>Some medicines can increase the amount of cabergoline in your blood and so could increase the side effects, these include:</li><li>Medicines for Parkinson&rsquo;s disease</li><li>Medicines for severe migraine headaches (e.g. pergolide, bromocriptine, lisuride, ergotamine, dihydroergotamine, ergometrine or methysergide)</li><li>Antibiotics (e.g. erythromycin)</li></ul><p><strong>Nostifix with food and drink</strong></p><p>See section 3 &lsquo;How to take Nostifix&rsquo;.</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p><em>Pregnancy</em></p><p>If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. You should also take care not to become pregnant for at least one month once you have stopped taking this medicine. If you become pregnant during treatment with Nostifix, stop taking Nostifix and inform your doctor who will then monitor your pregnancy as Nostifix can result in congenital abnormalities if you use it during pregnancy.</p><p><em>Breast-feeding </em></p><p>As Nostifix will stop you producing milk for your baby, you should not take this medicine if you plan to breast-feed. If you need to take Nostifix you should use another method of feeding your baby.</p><p><strong>Driving and using machines </strong></p><p>Cabergoline can cause drowsiness (somnolence) and sudden sleepy episodes, in some cases without any warning signs or awareness. You are advised not to drive or operate machines or engage in activities requiring mental alertness or coordination during treatment with this medicine. Your doctor will decide if you can continue treatment on Nostifix if this occurs</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>It is recommended you take Nostifix with or after food to help reduce feelings of nausea or vomiting.</p><ul><li>To prevent milk production (lactation): You should take 1 mg (two 0.5 mg tablets) on the first day after delivery.</li><li>To stop lactation once you have started to breast-feed: You should take 0.25 mg (one half of Nostifix 0.5 mg tablet) every 12 hours for two days.</li><li>To reduce prolactin levels in other conditions: You should initially take one 0.5 mg tablet (to be taken in two doses) spread out over a week (e.g. half a tablet on Monday and the other half of the tablet on Thursday). Your dose will be increased up to a maximum dose of 4.5 mg per week or until you have responded fully to treatment. The maximum dose should not exceed 3 mg per day.</li></ul><p>When you first start taking the tablet, it is recommended you slowly change position when trying to sit, stand or lie down, this is because this medicine may cause a drop in blood pressure that could make you dizzy when you move from a position. It is also recommended that you avoid alcohol and other medicines that cause drowsiness as this could increase the risk of dizziness.</p><p>During treatment your doctor may need to check your blood pressure, particularly in the first few days of treatment. A gynaecological assessment may also be carried out on the cells of your cervix or womb lining.</p><p><strong>If you take more </strong><strong>Nostifix </strong><strong>than you should</strong></p><p>If you take too many Nostifix Tablets, contact your doctor immediately or go to the nearest hospital casualty department. Symptoms of overdose may include nausea, vomiting, gastric complaints, low blood pressure when standing, confusion/psychosis or hallucinations.</p><p><strong>If you forget to take </strong><strong>Nostifix</strong></p><p>If you forget to take a dose take the next one as normal and tell your doctor if you have trouble remembering to take your tablets. Do not take a double dose to make up for a forgotten dose.</p><p><strong>If you stop taking </strong><strong>Nostifix</strong></p><p>Your doctor will advise you how long to take Nostifix. You should not stop until your doctor tells you.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong><em>Tell your doctor immediately if you experience any of the following symptoms after taking this medicine. These symptoms can be severe: </em></strong></p><ul><li>Abnormal or unusual thoughts.</li><li>Heart valve and related disorders e.g. inflammation (pericarditis) or leaking of fluid in the pericardium (pericardial effusion). This is a very common side effect (may affect more than 1 in 10 people). The early symptoms may be one or more of the following: Difficulty breathing, shortness of breath, pounding heart, feeling faint, chest pain, back pain, pelvic pain or swollen legs. These may be the first signs of a condition called pulmonary fibrosis, which can affect the lungs, heart/heart valves or lower back.</li><li>Development of a widespread itchy rash, difficulty breathing with or without wheezing, feeling faint, unexplained swelling of the body or tongue or any other symptoms which appear to come on rapidly after taking this medication and make you feel unwell. These may be indicative of an allergic reaction.</li></ul><p><strong><em>You may experience the following side effects: </em></strong></p><ul><li>Inability to resist the impulse, drive or temptation to perform an action that could be harmful to you or others, which may include:<ul><li>Strong impulse to gamble excessively despite serious personal or family consequences.</li><li>Aggression and altered or increased sexual interest and behaviour of significant concern to you or to others, for example, an increased sexual drive.</li><li>Uncontrollable excessive shopping or spending.</li><li>Binge eating (eating large amounts of food in a short time period) or compulsive eating (eating more food than normal and more than is needed to satisfy your hunger).</li></ul></li></ul><p>Tell your doctor if you experience any of these behaviours; they will discuss ways of managing or reducing the symptoms.</p><p><strong><em>During treatment you may also notice the following effects: </em></strong></p><ul><li><strong>Very common:</strong> May affect more than 1 in 10 people: Drowsiness, nausea, headache, dizziness, vertigo, stomach pain, indigestion, inflamed stomach lining, fatigue, lack of bodily strength, weakness.</li><li><strong>Common:</strong> May affect up to 1 in 10 people: Constipation, blurred vision, low blood pressure after childbirth which may not have any symptoms, breast pain, depression, sleep disturbances, excessive daytime drowsiness/sleepiness, vomiting, low blood pressure, hot flushes.</li><li><strong>Uncommon:</strong> May affect up to 1 in 100 people: Loss of hair, severe itching, hypersensitivity reaction, shortness of breath, fainting, nosebleed, leg cramps, swelling due to accumulation of fluid in the tissues (oedema), rash, irregular or strong heartbeat (palpitations), pins and needles sensation, decrease in haemoglobin in women whose periods had stopped and then re-started, temporary partial vision loss, cold hands and feet.</li><li><strong>Rare:</strong> May affect up to 1 in 1000 people: Pain in the stomach.</li><li><strong>Not known:</strong> Frequency cannot be estimated from the available data: Abnormal liver and abnormal blood tests of liver function, breathing problems with inadequate intake of oxygen, chest pain, tremor, an increase in the level of some enzymes in the blood, abnormal vision, episodes of sudden sleep onset, seeing or hearing things that are not really there (hallucinations), delusions, psychotic disorder</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Store below 30&deg;C.</p><p>Store in the original package.</p><p>Do not use this medicine after the expiry date which is stated on the package after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Do not use this medicine if you notice any visible signs of deterioration.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is cabergoline.</p><p>Each tablet of Nostifix 0.5 mg Tablets contains 0.5 mg cabergoline.</p><p>The other ingredients are microcrystalline cellulose, citric acid and magnesium stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Nostifix 0.5 mg Tablets are white to off-white scored oblong-shaped tablet embossed with ‘JI’ on one side and ‘161’ on the other side in PVC/Aclar-aluminum blisters.
Pack sizes: 2 and/or 8 Tablets.
Not all pack sizes maybe marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder, Batch releaser and Bulk manufacturer</strong></p><p>Jazeera Pharmaceutical Industries<br />Al-Kharj Road<br />P.O. Box 106229<br />Riyadh 11666, Saudi Arabia<br />Tel: + (966-11) 8107023, + (966-11) 2142472<br />Fax: + (966-11) 2078170<br />e-mail: SAPV@hikma.com<u> </u></p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects, you can also help provide more information on the safety of this medicine.</p><p>&middot;&nbsp;&nbsp;&nbsp; Saudi Arabia</p><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp; Other GCC States</p><p>Please contact the relevant competent authority.</p><p>&middot;&nbsp;&nbsp;&nbsp; United Arab of Emirates</p><p>Pharmacovigilance &amp; Medical Device Section</p><p>P.O. Box: 1853</p><p>Tel: 80011111</p><p>Email: pv@mohap.gov.ae</p><p>Drug Department</p><p>Ministry of Health &amp; Prevention</p><p>Duba</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 07/2024; version number SA3.0.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <ul dir="rtl"><li>يحتوي نوستيفيكس على المادة الفعّالة كابيرجولين. ينتمي هذا الدواء إلى فئة من الأدوية تسمى &quot;ناهضات الدوبامين&quot;. يتم تصنيع الدوبامين بشكل طبيعي في الجسم ويساعد على نقل الرسائل إلى الدماغ.</li><li>يستخدم نوستيفيكس لإيقاف إفراز حليب الثدي (حليب الرضاعة) بعد فترة قليلة من الولادة، ولادة جنين متوفي، الإجهاض أو الإسقاط. يمكن أيضاً استخدامه إذا كنت لا ترغبين في الاستمرار في إرضاع طفلك رضاعة طبيعية بعد البدء في إرضاعه.</li><li>كما يمكن استخدام نوستيفيكس لعلاج الحالات الأخرى الناجمة عن الاضطرابات الهرمونية التي يمكن أن تؤدي إلى مستويات عالية من هرمون البرولاكتين الذي يتم تصنيعه. هذا يشمل قلة فترات الحيض، وحيض غير منتظم وخفيف جداً، فترات حيض لا يحدث فيها إباضة وإفراز الحليب من الثدي دون الرضاعة الطبيعية. أيضاً في الحالات التي تكون فيها مستويات البرولاكتين المرتفعة ناتجة عن أسباب غير معروفة (فرط برولاكتين الدم مجهول السبب) أو بسبب أورام الغدة النخامية عند كل من الرجال والنساء.</li><li>يحاكي كابيرجولين عمل الدوبامين لتقليل إنتاج البرولاكتين في الدم. برولاكتين هو الهرمون الذي يحفز الثدي على إفراز الحليب.</li><li>يجب أن يستخدم نوستيفيكس لدى البالغين فقط. هو غير مناسب للأطفال تحت عمر 16 سنة.</li><li>يجب عليكِ التحدث مع الطبيب أو الصيدلي إذا كنتِ لا تشعرين بالتحسن أو إذا كنتِ تشعرين بأن حالتك تزداد سوءاً.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناولي نوستيفيكس</strong></p><ul dir="rtl"><li>إذا كنتِ تعانين من حساسية لمادة الكابيرجولين، لأدوية أخرى تسمى قلويات الأرغوت، (على سبيل المثال: البيرجوليد، البروموكريبتين، الليزوريد، الإرجوتامين أو الإرجومترين) أو لأي من المكونات الأخرى لهذا الدواء (المذكورة في القسم 6)</li><li>إذا كنتِ تعانين من مرض شديد في الكبد</li><li>إذا كنتِ تعانين من ارتفاع في ضغط الدم أثناء الحمل يصاحبه تورم وبروتين في البول (تسمم الحمل)</li><li>إذا كان يتم علاجك بمضادات الذهان أو عانيت مسبقاً من أمراض نفسية مرتبطة بالولادة (الذهان النفاسي)</li><li>إذا كنتِ حاملاً أو تقومين بالرضاعة الطبيعية</li><li>إذا كان سيتم علاجك بنوستيفيكس لفترة طويلة ولديك صمامات قلبية متصلّبة وملتهبة (اعتلال الصمام القلبي)</li><li>إذا كان لديك ردود فعل تليّفيّة (نسيج ندبي) تؤثر على البطن، القلب أو الرئتين</li></ul><p dir="RTL"><strong>الاحتياطات والتحذيرات </strong></p><p dir="RTL">تحدثي إلى الطبيب أو الصيدلي قبل تناول نوستيفيكس إذا كنتِ تعانين أو عانيت في السابق من أي من الحالات التالية:</p><ul dir="rtl"><li>مرض يصيب القلب والأوعية الدموية (مرض قلبي وعائي)</li><li>برودة اليدين والقدمين (متلازمة راينود)</li><li>ألم مستمر في البطن عند الجوع (القرحة الهضمية) أو نزيف من المعدة والأمعاء (نزيف الجهاز الهضمي)</li><li>عانيت مسبقاً من مرض نفسي خطير، خصوصاً الاضطرابات الذهانية</li><li>انخفاض وظائف الكبد</li><li>خلل في وظائف الكلى أو مرض في الكلى</li><li>ارتفاع ضغط الدم بعد الولادة</li><li>ردود فعل تليّفيّة (نسيج ندبي) تؤثر على القلب، الرئتين أو البطن. في حال علاجك بنوستيفيكس لفترة طويلة، سوف يفحص طبيبك قبل البدء في العلاج ما إذا كان قلبك، رئتيك وكليتيك بحالة جيدة. سيقوم الأطباء أيضاً بإجراء مخطط صدى القلب (فحص بالموجات فوق الصوتية للقلب) قبل بدء العلاج وعلى فترات منتظمة أثناء العلاج. يجب أن يتم إيقاف العلاج في حال حدوث ردود فعل تليّفيّة</li><li>انخفاض ضغط الدم (انخفاض ضغط الدم الوضعي) أو في حال تناول أي أدوية لخفض ضغط الدم</li></ul><p dir="RTL">إذا كنت قد ولدت للتو، فقد تكونين أكثر عرضة للإصابة بحالات معينة. قد تشمل هذه الحالات ارتفاع ضغط الدم، نوبة قلبية، تشنج، سكتة دماغية أو مشاكل صحية عقلية. لذلك، سيحتاج طبيبك إلى فحص ضغط الدم بانتظام أثناء العلاج. تحدث إلى طبيبك على الفور إذا كنت تعاني من ارتفاع ضغط الدم، ألم في الصدر أو صداع شديد أو مستمر بشكل غير عادي (مع أو بدون مشاكل في الرؤية).</p><p dir="RTL">أخبري طبيبك إذا لاحظت أنت أو أسرتك/مقدم الرعاية أنك تظهرين إلحاحاً أو رغبة في التصرف بطرق غير مألوفة بالنسبة لك ولا يمكنك مقاومة الدافع، التّوجه أو الاستمالة للقيام بأنشطة معينة قد تضرك أو تضر الآخرين. تسمى هذه اضطرابات التحكم في الاندفاع ويمكن أن تشمل سلوكيات مثل لعب القمار الإدماني، الإفراط في الأكل أو في الإنفاق، الدافع الجنسي العالي بشكل غير طبيعي أو زيادة في الأفكار أو المشاعر الجنسية. قد يحتاج طبيبك إلى تعديل الجرعة أو إيقافها.</p><p dir="RTL">يوصى بأن تخضع النساء اللواتي يتعالجن بنوستيفيكس لفترة طويلة الأمد من أجل علاج الاضطرابات الهرمونية للفحوصات النسائية بانتظام، بما في ذلك فحوصات اللطاخة. سيواصل طبيبك مراقبة حالتك الطبية أثناء تناولك أقراص نوستيفيكس.</p><p dir="RTL"><strong>الأدوية الأخرى ونوستيفيكس</strong></p><p dir="RTL">أخبري طبيبك أو الصيدلي إذا كنت تتناولين، تناولت مؤخراً أو قد تتناولين أي أدوية أخرى، بما في ذلك الأدوية التي يتم صرفها بدون وصفة طبية.</p><p dir="RTL">قد تقلل بعض الأدوية من فعالية كابيرجولين، وتشمل:</p><ul dir="rtl"><li>الأدوية المستخدمة لعلاج الأمراض النفسية (كالأدوية المضادة للذهان مثل الكلوربرومازين، الهالوبيريدول)</li><li>أدوية الغثيان والقيء (مثل: الدومبيريدون، الميتوكلوبراميد)</li></ul><p dir="RTL">قد تزيد بعض الأدوية من كمية كابيرجولين في دمك ومن ثم يمكن أن تزيد من الآثار الجانبية، وتشمل:</p><ul dir="rtl"><li>أدوية مرض باركنسون</li><li>أدوية علاج الصداع النصفي الشديد (مثل: البيرجوليد، البروموكريبتين، الليزوريد، الأرغوتامين، ثنائي الهيدرو أرغوتامين، الإرغومترين أو الميثيسرجيد)</li><li>المضادات الحيوية (مثل: الإريثروميسين)</li></ul><p dir="RTL"><strong>نوستيفيكس مع الطعام والشراب</strong></p><p dir="RTL">انظر القسم 3 &quot;طريقة تناول نوستيفيكس&quot;.</p><p dir="RTL"><strong>الحمل، الرضاعة والخصوبة</strong></p><p dir="RTL"><em>الحمل</em></p><p dir="RTL">يرجى استشارة طبيبك أو الصيدلي قبل تناول هذا الدواء إذا كنت حاملاً، تعتقدين بأنك حامل أو تخططين لذلك. يجب عليك أيضاً مراعاة عدم الحمل لمدة لا تقل عن شهر حالما تتوقفين عن تناول هذا الدواء. إذا أصبحت حاملاً أثناء العلاج بنوستيفيكس، فتوقفي عن تناول نوستيفيكس وأخبري طبيبك الذي سيقوم حينئذ بمتابعة حملك لأن نوستيفيكس قد يؤدي إلى حدوث تشوهات خلقية في حال استخدامه أثناء الحمل.</p><p dir="RTL"><em>الرضاعة الطبيعية </em></p><p dir="RTL">يجب عليك عدم تناول هذا الدواء إذا كنت تخططين للقيام بالرضاعة الطبيعية، لأن نوستيفيكس سيعمل على إيقاف إفراز الحليب لطفلك. إذا كان يجب عليك تناول نوستيفيكس، يجب عليك استخدام طريقة أخرى لتغذية طفلك.<strong>&nbsp;</strong></p><p dir="RTL"><strong>القيادة واستخدام الآلات </strong></p><p dir="RTL">قد يسبب كابيرجولين النعاس (نيمومة) ونوبات نوم مفاجئة، في بعض الحالات بدون أي علامات تنبيهية أو تحذيرية. ينصح بعدم القيادة أو تشغيل الآلات أو المشاركة في الأنشطة التي تتطلب تيقظاً عقلياً أو تنسيقاً حركياً أثناء العلاج بهذا الدواء. سيحدد طبيبك ما إذا كان يمكنك الاستمرار في العلاج بنوستيفيكس إذا حدث ذلك</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قومي دائماً بتناول دوائك كما وصفه لك طبيبك أو الصيدلي تماماً. تأكدي من طبيبك أو الصيدلي إذا كانت لديك أية استفسارات.</p><p dir="RTL">يوصى بتناول نوستيفيكس مع الطعام أو بعده للمساعدة على تقليل الشعور بالغثيان أو القيء.</p><ul dir="rtl"><li>لمنع إفراز الحليب (حليب الرضاعة): يجب عليكِ تناول 1 ملغم (قرصان من 0.5 ملغم) في أول يوم بعد الولادة.</li><li>لوقف إفراز الحليب عند بدء الرضاعة الطبيعية: يجب عليك تناول 0.25 ملغم (نصف قرص من نوستيفيكس 0.5 ملغم) كل 12 ساعة لمدة يومين.</li><li>لتقليل مستويات البرولاكتين في حالات أخرى: يجب في البداية تناول قرص واحد من 0.5 ملغم (يتم تناوله على جرعتين) موزعاً على الأسبوع (أي: نصف قرص يوم الإثنين والنصف الآخر يوم الخميس). ستتم زيادة جرعتك إلى أقصى جرعة تبلغ 4.5 ملغم أسبوعياً أو حتى تستجيب تماماً للعلاج. يجب ألا تتجاوز أقصى جرعة 3 ملغم يومياً.</li></ul><p dir="RTL">عند بدء تناول القرص لأول مرة، يوصى بتغيير وضعيتك ببطء عند محاولة الجلوس، القيام أو الاستلقاء، لأن هذا الدواء قد يسبب انخفاضاً في ضغط الدم وهو ما يترتب عليه شعور بدوخة عند التحرك من وضعية ما. يوصى كذلك بتجنب تناول الكحول والأدوية الأخرى التي تسبب النعاس لأن ذلك قد يؤدي إلى زيادة خطورة الشعور بالدوخة.</p><p dir="RTL">قد يتعين على طبيبك فحص ضغط الدم أثناء العلاج، خاصة في الأيام القليلة الأولى من العلاج. قد يتم أيضاً إجراء فحص نسائي على خلايا عنق الرحم أو بطانة الرحم.</p><p dir="RTL"><strong>إذا تناولت </strong><strong>نوستيفيكس أكثر من اللازم </strong></p><p dir="RTL">إذا تناولت الكثير من أقراص نوستيفيكس، اتصلي بطبيبك على الفور أو اذهبي إلى قسم الطوارئ في أقرب مستشفى. قد تشمل أعراض الجرعة الزائدة الغثيان، القيء، شكاوى من المعدة، انخفاض ضغط الدم عند الوقوف، ارتباك/ذهان أو هلوسات.</p><p dir="RTL"><strong>إذا نسيت تناول </strong><strong>نوستيفيكس</strong></p><p dir="RTL">إذا نسيت تناول جرعة، فتناولي الجرعة التالية على نحو طبيعي وأخبري طبيبك إذا كان لديك مشكلة في تذكر تناول أقراصك. لا تقومي بتناول جرعة مضاعفة للتعويض عن الجرعة المنسية.</p><p dir="RTL"><strong>إذا توقفت عن تناول </strong><strong>نوستيفيكس</strong></p><p dir="RTL">سوف ينصحك طبيبك بمدة تناول نوستيفيكس. يجب عدم التوقف ما لم يخبرك طبيبك.</p><p dir="RTL">إذا كان لديك أية أسئلة إضافية حول استخدام هذا الدواء، يرجى استشارة الطبيب أو الصيدلي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب هذا الدواء آثاراً جانبيةً، إلا أنه ليس بالضرورة أن تحدث لدى جميع مستخدمي هذا الدواء.</p><p dir="RTL"><strong><em>أخبري طبيبك على الفور إذا تعرضت لأي من الأعراض التالية بعد تناول هذا الدواء. قد تكون هذه الأعراض شديدة: </em></strong></p><ul dir="rtl"><li>أفكار غير طبيعية أو غير معتادة.</li><li>اضطرابات صمام القلب والاضطرابات التي تتعلق بها مثل: الالتهاب (التهاب التامور) أو تسرب السوائل في التامور (انصباب تاموري). هذا الأثر الجانبي شائع جداً (قد يؤثر على أكثر من شخص واحد من كل 10 أشخاص). قد تكون الأعراض المبكرة واحدة أو أكثر مما يلي: صعوبة التنفس، ضيق التنفس، خفقان القلب، الشعور بالإغماء، ألم في الصدر، ألم في الظهر، ألم في الحوض أو تورم الساقين. قد تكون هذه أولى علامات حالة يطلق عليها التليف الرئوي، الذي قد يؤثر على الرئتين، القلب/الصمامات القلبية أو أسفل الظهر.</li><li>ظهور طفح جلدي مثير للحكة منتشر على نطاق واسع، صعوبة التنفس مع أو بدون صفير، الشعور بالإغماء، تورم الجسد أو اللسان لأسباب غير معلومة أو غيرها من الأعراض التي تظهر سريعاً بعد تناول هذا الدواء وتسبب شعوراً بالتوعك. قد يكون ذلك دليلاً على رد فعل تحسسي.</li></ul><p dir="RTL"><strong><em>قد تظهر عليك أي من الآثار الجانبية التالية: </em></strong></p><ul dir="rtl"><li>عدم القدرة على مقاومة الدافع، الحافز أو الرغبة في القيام بتصرف قد يكون ضاراً لك أو للآخرين، ويشمل ذلك:<ul><li>الدافع القوي للمقامرة بصورة مفرطة على الرغم من العواقب الشخصية أو الأسرية الوخيمة.</li><li>العدوانية وزيادة الرغبة الجنسية أو تغيرها وسلوك مقلق كثيراً لك أو للآخرين، على سبيل المثال، زيادة الدافع الجنسي.</li><li>الإفراط في التسوق أو الإنفاق بطريقة لا يمكن السيطرة عليها.</li><li>تناول الطعام بنهم (تناول الطعام بكميات كبيرة في وقت قصير) أو تناول الطعام القهري (تناول الطعام أكثر من المعتاد وأكثر من الحاجة إلى إشباع الجوع).</li></ul></li></ul><p dir="RTL">أخبري طبيبك إذا تعرضت لأي من هذه السلوكيات؛ حيث سيناقش طرقاً للتحكم في هذه الأعراض أو تقليلها.</p><p dir="RTL"><strong><em>قد تلاحظين كذلك الآثار التالية أثناء العلاج: </em></strong></p><ul dir="rtl"><li><strong>شائعة جداً:</strong> قد تؤثر على أكثر من شخص واحد من كل 10 أشخاص: نعاس، غثيان، صداع، دوخة، دوار، ألم في المعدة، عسر الهضم، التهاب بطانة المعدة، تعب، نقص القوة الجسدية، ضعف.</li><li><strong>شائعة:</strong> قد تؤثر على ما يصل إلى شخص واحد من كل 10 أشخاص: إمساك، تشوش الرؤية، انخفاض ضغط الدم بعد الولادة والذي قد لا يكون له أي أعراض، ألم الثدي، اكتئاب، اضطرابات النوم، فرط النعاس/النوم بالنهار، قيء، انخفاض ضغط الدم، هبّات ساخنة.</li><li><strong>غير شائعة:</strong> قد تؤثر على ما يصل إلى شخص واحد من كل 100 شخص: تساقط الشعر، حكة شديدة، تفاعل فرط الحساسية، ضيق في التنفس، إغماء، نزيف بالأنف، تشنجات بالساق، تورم بسبب تراكم السوائل في الأنسجة (الوذمة)، طفح جلدي، نبضات قلب قوية أو غير منتظمة (خفقان)، شعور بالوخز والتنميل، انخفاض نسبة الهيموجلوبين عند النساء اللواتي انقطعت فترات الحيض لديهن ثم بدأت مجدداً، فقدان الرؤية جزئياً بشكل مؤقت، برودة اليدين والقدمين.</li><li><strong>نادرة:</strong> قد تؤثر على ما يصل إلى شخص واحد من كل 1000 شخص: ألم في المعدة.</li><li><strong>غير معروفة:</strong> لا يمكن تقدير مدى التكرار من البيانات المتاحة: اختلال وظائف الكبد، نتائج اختبارات دم غير طبيعية لوظائف الكبد، مشاكل في التنفس مع عدم وجود كمية كافية من الأوكسجين، ألم في الصدر، ارتعاش، زيادة مستوى بعض الإنزيمات في الدم، رؤية غير طبيعية، نوبات ظهور النوم المفاجئ، رؤية أشياء غير حقيقية أو سماعها (هلوسات)، أوهام، اضطراب ذهاني</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">يحفظ عند درجة حرارة أقل من 30&deg; مئوية.</p><p dir="RTL">يحفظ داخل العبوة الأصلية.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية بعد &ldquo;EXP&rdquo;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت أي علامات تلف واضحة عليه.</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه الإجراءات ستساعد في الحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعّالة هي كابيرجولين.</p><p dir="RTL">يحتوي كل قرص من نوستيفيكس 0,5 ملغم أقراص على 0,5 ملغم كابيرجولين.</p><p dir="RTL">المواد الأخرى المستخدمة في التركيبة التصنيعية هي سيلليلوز بلوري مكروي، حمض الستريك وستيرات المغنيسيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">نوستيفيكس 0,5 ملغم أقراص هي أقراص لونها أبيض مائل إلى الأبيض المصفر بيضاوية الشكل عليها خط للكسر منقوش على أحد جانبيها &lsquo;JI&rsquo; و&lsquo;161&rsquo; على الجانب الآخر في أشرطة من كلوريد متعدد الڤينيل/أكلار-الألومنيوم.</p><p dir="RTL">أحجام العبوات: قرصان و/أو 8 أقراص.</p><p dir="RTL">قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق، محرر التشغيلة والشركة المصنعة للمستحضر النهائي</strong></p><p dir="RTL">شركة الجزيرة للصناعات الدوائية<br />طريق الخرج<br />صندوق بريد 106229<br />الرياض 11666، المملكة العربية السعودية</p><p dir="RTL">هاتف: 8107023 (11-966) +، 2142472 (11-966) +<br />فاكس: 2078170 (11-966) +<br />البريد الإلكتروني:SAPV@hikma.com</p><p dir="RTL"><strong>للإبلاغ</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>الآثار</strong><strong> </strong><strong>الجانبية</strong></p><p dir="RTL">تحدث إلى الطبيب، الصيدلي، أو الممرض إذا عانيت من أية آثار جانبية. وذلك يشمل أي آثار جانبية لم يتم ذكرها في هذه النشرة. كما أنه يمكنك الإبلاغ عن هذه الآثار مباشرةً (انظر التفاصيل المذكورة أدناه). من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة بتوفير معلومات مهمة عن سلامة الدواء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; المملكة العربية السعودية</p><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><p dir="RTL">مركز الاتصال الموحد: 19999</p><p dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني: &nbsp;https://ade.sfda.gov.sa</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; دول الخليج العربي الأخرى</p><p dir="RTL">الرجاء الاتصال بالجهات الوطنية في كل دولة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; الإمارات العربية المتحدة</p><p>قسم اليقظة الدوائية والجهاز الطبي</p><p>صندوق بريد: 1853</p><p>هاتف: 80011111</p><p dir="RTL">البريد الإلكتروني: pv@mohap.gov.ae</p><p>إدارة الدواء</p><p>وزارة الصحة ووقاية المجتمع</p><p dir="RTL">دبي</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 07/2024، رقم النسخة: SA3.0.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Nostifix 0.5 mg Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 0.5 mg cabergoline.

For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablets.
White to off-white scored oblong-shaped tablet embossed with ‘JI’ on one side and ‘161’ on the other side.
The tablet can be divided into equal doses.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Inhibition/suppression of physiological lactation</strong></p><p>Cabergoline is indicated for the inhibition of physiological lactation soon after delivery and for suppression of already established lactation:</p><ol><li>After parturition, when the mother elects not to breast feed the infant or when breast feeding is contraindicated due to medical reasons related to the mother or the new-born.</li><li>After stillbirth or abortion.</li></ol><p>Cabergoline prevents/suppresses physiological lactation by inhibiting prolactin secretion.</p><p>In controlled clinical trials, cabergoline given as a single 1 mg administration during the first day post-partum, was effective in inhibiting milk secretion, as well as breast engorgement and pain in 70 - 90% of the women. Less than 5% of women experienced rebound breast symptomatology during the third post-partum week (which was usually mild in severity).</p><p>Suppression of milk secretion and relief of breast engorgement and pain are obtained in approximately 85% of nursing women treated with a total dose of 1 mg cabergoline given in four divided doses over two days. Rebound breast symptomatology after day 10 is uncommon (approximately 2% of cases).</p><p><strong>Treatment of hyperprolactinaemic disorders</strong></p><p>Cabergoline is indicated for the treatment of dysfunctions associated with hyperprolactinaemia, including amenorrhoea, oligomenorrhoea, anovulation and galactorrhoea. Cabergoline is indicated in patients with prolactin-secreting pituitary adenomas (micro- and macroprolactinomas), idiopathic hyperprolactinaemia, or empty sella syndrome with associated hyperprolactinaemia, which represent the basic underlying pathologies contributing to the above clinical manifestations.</p><p>On chronic therapy, cabergoline at doses ranging between 1 and 2 mg per week, was effective in normalising serum prolactin levels in approximately 84% of hyperprolactinaemic patients. Regular cycles were resumed in 83% of previously amennorhoeic women. Restoration of ovulation was documented in 89% of women with progesterone levels monitored during the luteal phase. Galactorrhoea disappeared in 90% of cases showing this symptom before therapy. Reduction in tumour size was obtained in 50 - 90% of female and male patients with micro- or macroprolactinoma.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cabergoline is to be administered by the oral route. Since in clinical studies cabergoline has been mainly administered with food and since the tolerability of this class of compounds is improved with food, it is recommended that cabergoline be preferably taken with meals for all the therapeutic indications.</p><p><strong>Inhibition/suppression of physiological lactation</strong></p><p>For inhibition of lactation cabergoline should be administered during the first day post-partum. The recommended therapeutic dose is 1 mg (two 0.5 mg tablets) given as a single dose.</p><p>For suppression of established lactation the recommended therapeutic dosage regimen is 0.25 mg (one-half 0.5 mg tablet) every 12 hours for two days (1 mg total dose). This dosage regimen has been demonstrated to be better tolerated than the single dose regimen in women electing to suppress lactation having a lower incidence of adverse events, in particular of hypotensive symptoms.</p><p><strong>Treatment of hyperprolactinaemic disorders</strong></p><p>The recommended initial dosage of cabergoline is 0.5 mg per week given in one or two (one-half of one 0.5 mg tablet) doses (e.g. on Monday and Thursday) per week. The weekly dose should be increased gradually, preferably by adding 0.5 mg per week at monthly intervals until an optimal therapeutic response is achieved. The therapeutic dosage is usually 1 mg per week and ranges from 0.25 mg to 2 mg per week. Doses of cabergoline up to 4.5 mg per week have been used in hyperprolactinaemic patients.</p><p>The maximum dose should not exceed 3 mg per day.</p><p>The weekly dose may be given as a single administration or divided into two or more doses per week according to patient tolerability. Division of the weekly dose into multiple administrations is advised when doses higher than 1 mg per week are to be given since the tolerability of doses greater than 1 mg taken as a single weekly dose has been evaluated only in a few patients.</p><p>Patients should be evaluated during dose escalation to determine the lowest dosage that produces the therapeutic response. Monitoring of serum prolactin levels at monthly intervals is advised since, once the effective therapeutic dosage regimen has been reached, serum prolactin normalisation is usually observed within two to four weeks.</p><p>After cabergoline withdrawal, recurrence of hyperprolactinaemia is usually observed. However, persistent suppression of prolactin levels has been observed for several months in some patients. Of the group of women followed up, 23/29 had ovulatory cycles which continued for greater than 6 months after cabergoline discontinuation.</p><p><strong>Paediatric population</strong></p><p>The safety and efficacy of cabergoline has not been established in subjects less than 16 years of age.</p><p><strong>Use in the elderly</strong></p><p>As a consequence of the indications for which cabergoline is presently proposed, the experience in elderly is very limited. Available data do not indicate a special risk.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to cabergoline, any of the excipients listed in section 6.1 or any ergot alkaloid.
History of pulmonary, pericardial and retroperitoneal fibrotic disorders.
Cabergoline is contraindicated in patients with hepatic insufficiency and with toxaemia of pregnancy. Cabergoline should not be co-administered with anti-psychotic medications or administered to women with a history of puerperal psychosis.
For long-term treatment: Evidence of cardiac valvulopathy as determined by pre-treatment echocardiography. (See section 4.4).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>General:</strong></p><p>The safety and efficacy of cabergoline have not yet been established in patients with renal and hepatic disease. As with other ergot derivatives, cabergoline should be given with caution to patients with severe cardiovascular disease, Raynaud&#39;s syndrome, renal insufficiency, peptic ulcer or gastrointestinal bleeding, or with a history of serious, particularly psychotic, mental disorders. Particular care should be taken when patients are taking concomitant psychoactive medication.</p><p>Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p>Symptomatic hypotension can occur with cabergoline administration for any indication. Care should be exercised when administering cabergoline concomitantly with other drugs known to lower blood pressure.</p><p>The effects of alcohol on overall tolerability of cabergoline are currently unknown.</p><p>Before cabergoline administration, pregnancy should be excluded and after treatment pregnancy should be prevented for at least one month.</p><p><strong>Hepatic Insufficiency:</strong></p><p>Lower doses should be considered in patients with severe hepatic insufficiency who receive prolonged treatment with cabergoline. Compared to normal volunteers and those with lesser degrees of hepatic insufficiency, an increase in AUC has been seen in patients with severe hepatic insufficiency (Child-Pugh Class C) who received a single 1 mg dose.</p><p><strong>Postural Hypotension:</strong></p><p>Postural hypotension can occur following administration of cabergoline. Care should be exercised when administering cabergoline concomitantly with other drugs known to lower blood pressure.</p><p><strong>Somnolence/Sudden Sleep Onset:</strong></p><p>Cabergoline has been associated with somnolence. Dopamine agonists can be associated with sudden sleep onset episodes in patients with Parkinson&#39;s disease. Sudden onset of sleep during daily activities, in some cases without awareness or warning signs, has been reported uncommonly. Patients must be informed of this and advised to exercise caution while driving or operating machines during treatment with cabergoline. Patients who have experienced somnolence and/or an episode of sudden sleep onset must refrain from driving or operating machines. Furthermore a reduction in dosage or termination of therapy may be considered. (See section 4.7)</p><p><strong>Impulse control disorders:</strong></p><p>Patients should be regularly monitored for the development of impulse control disorders. Patients and carers should be made aware that behavioural symptoms of impulse control disorders including pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists including cabergoline. Dose reduction/tapered discontinuation should be considered if such symptoms develop.</p><p><strong>Inhibition/suppression of physiological lactation:</strong></p><p>As with other ergot derivatives, cabergoline should not be used in women with pregnancy-induced hypertension, for example, preeclampsia or post-partum hypertension, unless the potential benefit is judged to outweigh the possible risk.</p><p>Serious adverse events including hypertension, myocardial infarction, seizures, stroke or psychiatric disorders have been reported in postpartum women treated with cabergoline for inhibition of lactation. In some patients the development of seizures or stroke was preceded by severe headache and/or transient visual disturbances. Blood pressure should be carefully monitored after the treatment. If hypertension, suggestive chest pain, severe, progressive, or unremitting headache (with or without visual disturbances), or evidence of central nervous system toxicity develop, cabergoline should be discontinued and the patient should be evaluated promptly.</p><p>In post-partum studies with cabergoline, blood pressure decreases were mostly asymptomatic and were frequently observed on a single occasion 2 to 4 days after treatment. Since decreases in blood pressure are frequently noted during the puerperium, independently of drug therapy, it is likely that many of the observed decreases in blood pressure after cabergoline administration were not drug-induced. However, periodic monitoring of blood pressure, particularly during the first few days after cabergoline administration, is advised.</p><p>A single dose of 0.25 mg of cabergoline should not be exceeded in nursing women treated for suppression of established lactation to avoid potential postural hypotension (see section 4.2). A clinical study exploring the efficacy and tolerability of 0.5 mg of cabergoline given as a single dose for suppression of lactation has shown that the risk of side effects is approximately doubled in this indication if the drug is administered as a single dose of 0.5 mg.</p><p><strong>Treatment of hyperprolactinaemic disorders:</strong></p><p>Because hyperprolactinaemia accompanied with amenorrhoea/galactorrhoea and infertility may be associated with pituitary tumour, a complete evaluation of the pituitary is indicated before treatment with cabergoline is initiated.</p><p>Cabergoline restores ovulation and fertility in women with hyperprolactinaemic hypogonadism.</p><p>Because pregnancy might occur prior to reinitiation of menses, a pregnancy test is recommended at least every four weeks during the amenorrhoeic period and, once menses are reinitiated, every time a menstrual period is delayed by more than three days. Women who wish to avoid pregnancy should be advised to use mechanical contraception during treatment with cabergoline and after discontinuation of cabergoline until recurrence of anovulation. As a precautionary measure, women who become pregnant should be monitored to detect signs of pituitary enlargement since expansion of pre-existing pituitary tumours may occur during gestation.</p><p>Before administration of cabergoline, pregnancy should be excluded. Because clinical experience is still limited and the product has a long half-life, as a precautionary measure it is recommended that once regular ovulatory cycles have been achieved women seeking pregnancy discontinue cabergoline one month before intended conception. Should pregnancy occur during treatment, cabergoline is to be discontinued. As a precautionary measure, women who become pregnant should be monitored to detect signs of pituitary enlargement since expansion of pre-existing pituitary tumours may occur during gestation.</p><p>Regular gynaecological assessment, including cervical and endometrial cytology, is recommended for patients taking cabergoline for extensive periods.</p><p><strong>Fibrosis and cardiac valvulopathy and possibly related clinical phenomena:</strong></p><p>Fibrotic and serosal inflammatory disorders such as pleuritis, pleural effusion, pleural fibrosis, pulmonary fibrosis, pericarditis, pericardial effusion, cardiac valvulopathy involving one or more valves (aortic, mitral and tricuspid) or retroperitoneal fibrosis have occurred after prolonged usage of ergot derivatives with agonist activity at the serotonin 5HT2B receptor, such as cabergoline. In some cases, symptoms or manifestations of cardiac valvulopathy improved after discontinuation of cabergoline.</p><p>Erythrocyte sedimentation rate (ESR) has been found to be abnormally increased in association with pleural effusion/fibrosis. Chest x-ray examination is recommended in cases of unexplained ESR increases to abnormal values.</p><p>Valvulopathy has been associated with cumulative doses, therefore, patients should be treated with the lowest effective dose. At each visit, the risk benefit profile of cabergoline treatment for the patient should be reassessed to determine the suitability of continued treatment with cabergoline.</p><p><strong>Before initiating long-term treatment:</strong></p><p>All patients must undergo a cardiovascular evaluation, including echocardiogram to assess the potential presence of asymptomatic valvular disease. It is also appropriate to perform baseline investigations of erythrocyte sedimentation rate or other inflammatory markers, lung function/chest X-ray and renal function prior to initiation of therapy. In patients with valvular regurgitation, it is not known whether cabergoline treatment might worsen the underlying disease. If fibrotic valvular disease is detected, the patient should not be treated with cabergoline (see section 4.3).</p><p><strong>During long-term treatment:</strong></p><p>Fibrotic disorders can have an insidious onset and patients should be regularly monitored for possible manifestations of progressive fibrosis. Therefore, during treatment, attention should be paid to the signs and symptoms of:</p><ul><li>Pleuro-pulmonary disease such as dyspnoea, shortness of breath, persistent cough or chest pain.</li><li>Renal insufficiency or ureteral/abdominal vascular obstruction that may occur with pain in the loin/flank and lower limb oedema as well as any possible abdominal masses or tenderness that may indicate retroperitoneal fibrosis.</li><li>Cardiac failure: cases of valvular and pericardial fibrosis have often manifested as cardiac failure. Therefore, valvular fibrosis (and constrictive pericarditis) should be excluded if such symptoms occur.</li></ul><p>Clinical diagnostic monitoring for development of fibrotic disorders, as appropriate, is essential. Following treatment initiation, the first echocardiogram must occur within 3-6 months, thereafter, the frequency of echocardiographic monitoring should be determined by appropriate individual clinical assessment with particular emphasis on the above-mentioned signs and symptoms, but must occur at least every 6 to 12 months.</p><p>Cabergoline should be discontinued if an echocardiogram reveals new or worsened valvular regurgitation, valvular restriction or valve leaflet thickening (see section 4.3).</p><p>The need for other clinical monitoring (e.g. physical examination including, cardiac auscultation, X-ray, CT scan) should be determined on an individual basis.</p><p>Additional appropriate investigations such as erythrocyte sedimentation rate, and serum creatinine measurements should be performed if necessary to support a diagnosis of a fibrotic disorder</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The concomitant use of other drugs during early puerperium, particularly of ergot alkaloids, was not associated with detectable interactions modifying the efficacy and safety of cabergoline.</p><p>No information is available about the interaction between cabergoline and other ergot alkaloids; therefore, the concomitant use of these medications during long-term treatment with cabergoline is not recommended.</p><p>Since cabergoline exerts its therapeutic effect by direct stimulation of dopamine receptors, it should not be concurrently administered with drugs which have dopamine-antagonist activity (such as phenothiazines, butyrophenones, thioxanthenes, metoclopramide) since these might reduce the prolactin-lowering effect of cabergoline.</p><p>As with other ergot derivatives, cabergoline should not be used with macrolide antibiotics (e.g. erythromycin) due to increased systemic bioavailability of cabergoline.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no adequate and well-controlled studies from the use of cabergoline in pregnant women. Animal studies have not demonstrated teratogenic effects, but reduced fertility and embryo-toxicity were observed in association with pharmacodynamic activity (see section 5.3).</p><p>In a twelve year observational study on pregnancy outcomes following cabergoline therapy, information is available on 256 pregnancies. Seventeen of these 256 pregnancies (6.6%) eventuated in major congenital malformations or abortion. Information is available on 23/258 infants who had a total of 27 neonatal abnormalities, both major and minor. Musculoskeletal malformations were the most common neonatal abnormality (10), followed by cardio-pulmonary abnormalities (5). There is no information on perinatal disorders or long-term development of infants exposed to intra-uterine cabergoline. Based on recent published literature, the prevalence of major congenital malformations in the general population has been reported to be 6.9% or greater. Rates of congenital abnormality vary between different populations. It is not possible to accurately determine if there is an increased risk as no control group was included.</p><p>Cabergoline should only be used during pregnancy if clearly indicated and after an accurate benefit/risk evaluation. (See section 4.4).</p><p>Due to the long half-life of the drug and limited data on in utero exposure, women planning to become pregnant should discontinue cabergoline one month before intended conception. If conception occurs during therapy, treatment should be discontinued as soon as pregnancy is confirmed to limit foetal exposure to the drug.</p><p>In rats, cabergoline and/or its metabolites are excreted in milk. No information is available on the excretion in breast milk in humans; however, mothers should be advised not to breast-feed in case of failed lactation inhibition/suppression by cabergoline. Since it prevents lactation, cabergoline should not be administered to mothers with hyperprolactinemic disorders who wish to breast-feed their infants.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients should be careful when performing actions which require fast and accurate reaction during treatment initiation.</p><p>During the first days of cabergoline administration, patients should be cautioned about re-engaging in activities requiring rapid and precise responses such as driving an automobile or operating machinery.</p><p>Patients being treated with cabergoline and presenting with somnolence must be informed to refrain from driving or engaging in activities where impaired alertness may put themselves and others at risk of serious injury or death (e.g. operating machines) until such episodes and somnolence have resolved. (See section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse events are generally dose-related. In patients known to be intolerant to dopaminergic drugs, the likelihood of adverse events may be lessened by starting therapy with cabergoline at reduced doses, e.g. 0.25 mg once a week, with subsequent gradual increase until the therapeutic dosage is reached. If persistent or severe adverse events occur, temporary reduction of dosage followed by a more gradual increase, e.g. increments of 0.25 mg/week every two weeks, may increase tolerability.</p><p>The following undesirable effects have been observed and reported during treatment with cabergoline with the following frequencies: Very common (&ge; 1/10); common (&ge; 1/100 to &lt;1/10); uncommon (&ge; 1/1,000 to &le; 1/100); rare (&ge; 1/10,000 to &le; 1/1,000); very rare (&le; 1/10,000), not known (cannot be estimated from the available data).</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>MedDRA</strong></p><p><strong>System Organ Class</strong></p></td><td><p><strong>Frequency</strong></p></td><td><p><strong>Undesirable Effects</strong></p></td></tr><tr><td rowspan="3"><p><strong>Cardiac disorders</strong></p></td><td><p>Very Common</p></td><td><p>Valvulopathy (including regurgitation) and related disorders (pericarditis and pericardial effusion)</p></td></tr><tr><td><p>Uncommon</p></td><td><p>Palpitations</p></td></tr><tr><td><p>Not Known</p></td><td><p>Angina pectoris</p></td></tr><tr><td rowspan="3"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td><p>Uncommon</p></td><td><p>Dyspnea, pleural effusion, fibrosis, (including pulmonary fibrosis), epistaxis</p></td></tr><tr><td><p>Very rare</p></td><td><p>Pleural fibrosis</p></td></tr><tr><td><p>Not Known</p></td><td><p>Respiratory disorder, respiratory failure, pleuritis, chest pain</p></td></tr><tr><td><p><strong>Immune system disorders</strong></p></td><td><p>Uncommon</p></td><td><p>Hypersensitivity reaction</p></td></tr><tr><td rowspan="4"><p><strong>Nervous system disorders</strong></p></td><td><p>Very common</p></td><td><p>Headache*, dizziness/vertigo*</p></td></tr><tr><td><p>Common</p></td><td><p>somnolence</p></td></tr><tr><td><p>Uncommon</p></td><td><p>Transient hemianopsia, syncope, paresthesia</p></td></tr><tr><td><p>Not Known</p></td><td><p>Sudden sleep onset, tremor</p></td></tr><tr><td><p><strong>Eye disorders</strong></p></td><td><p>Not Known</p></td><td><p>Visual impairment</p></td></tr><tr><td rowspan="3"><p><strong>Psychiatric disorders</strong></p></td><td><p>Common</p></td><td><p>Depression</p></td></tr><tr><td><p>Uncommon</p></td><td><p>Increased libido</p></td></tr><tr><td><p>Not Known</p></td><td><p>Aggression, delusions, hypersexuality, pathological gambling, psychotic disorder, hallucinations</p></td></tr><tr><td rowspan="2"><p><strong>Vascular disorders</strong></p></td><td><p>Common</p></td><td><p>Cabergoline generally exerts a hypotensive effect in patients on long-term treatment; Postural hypotension, hot flushes**</p></td></tr><tr><td><p>Uncommon</p></td><td><p>Digital vasospasm, fainting</p></td></tr><tr><td rowspan="3"><p><strong>Gastrointestinal disorders</strong></p></td><td><p>Very common</p></td><td><p>Nausea*, dyspepsia, gastritis, abdominal pain*</p></td></tr><tr><td><p>Common</p></td><td><p>Constipation, vomiting**</p></td></tr><tr><td><p>Rare</p></td><td><p>Epigastric pain</p></td></tr><tr><td rowspan="2"><p><strong>General disorders and administration site conditions</strong></p></td><td><p>Very Common</p></td><td><p>Asthenia***, fatigue</p></td></tr><tr><td><p>Uncommon</p></td><td><p>Oedema, peripheral oedema</p></td></tr><tr><td><p><strong>Hepato-biliary disorders</strong></p></td><td><p>Not Known</p></td><td><p>Hepatic function abnormal</p></td></tr><tr><td><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td><p>Uncommon</p></td><td><p>Rash, alopecia</p></td></tr><tr><td><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td><p>Uncommon</p></td><td><p>Leg cramps</p></td></tr><tr><td><p><strong>Reproductive system and breast disorders</strong></p></td><td><p>Common</p></td><td><p>Breast pain</p></td></tr><tr><td rowspan="3"><p><strong>Investigations</strong></p></td><td><p>Common</p></td><td><p>Asymptomatic decreases in blood pressure (&ge; 20 mmHg systolic and &ge; 10 mmHg diastolic)</p></td></tr><tr><td><p>Uncommon</p></td><td><p>A decrease in haemoglobin values have been observed in amenhorrheic women during the first few months after menses.</p></td></tr><tr><td><p>Not Known</p></td><td><p>Blood creatinine phosphokinase increased, liver function tests abnormal</p></td></tr></tbody></table><p>*Very common in patients treated for hyperprolactinaemin disorders; Common in patients treated for inhibition/supression of lactation</p><p>** Common in patients treated for hyperprolactinaemin disorders; Uncommon in patients treated for inhibition/supression of lactation</p><p>*** Very common in patients treated for hyperprolactinaemin disorders; Uncommon in patients treated for inhibition/supression of lactation</p><p><strong>Impulse control disorders</strong></p><p>Pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists including cabergoline (see section 4.4).</p><p><strong>Reporting of suspected adverse reactions</strong></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>Saudi Arabia</p><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https: ade.sfda.gov.sa</p><p>Other GCC States</p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms of overdose would likely be those of over-stimulation of dopamine receptors e.g. nausea, vomiting, gastric complaints, postural hypotension, confusion/psychosis or hallucinations.</p><p>Supportive measures should be taken to remove any unabsorbed drug and maintain blood pressure, if necessary. In addition, the administration of dopamine antagonist drugs may be advisable.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Prolactine inhibitors, ATC code: G02CB03</p><p>Cabergoline is a dopaminergic ergoline derivative endowed with a potent and long-lasting PRL-lowering activity. It acts by direct stimulation of the D2-dopamine receptors on pituitary lactotrophs, thus inhibiting PRL secretion. In rats the compound decreases PRL secretion at oral doses of 3-25 mcg/kg, and in-vitro at a concentration of 45 pg/ml. In addition, cabergoline exerts a central dopaminergic effect via D2 receptor stimulation at oral doses higher than those effective in lowering serum PRL levels. The long lasting PRL-lowering effect of cabergoline is probably due to its long persistence in the target organ as suggested by the slow elimination of total radioactivity from the pituitary after single oral dose in rats (t&frac12; of approximately 60 hours).</p><p>The pharmacodynamic effects of cabergoline have been studied in healthy volunteers, puerperal women and hyperprolactinaemic patients. After a single oral administration of cabergoline (0.3 - 1.5 mg), a significant decrease in serum PRL levels was observed in each of the populations studied. The effect is prompt (within 3 hours from administration) and persistent (up to 7 - 28 days in healthy volunteers and hyperprolactinaemic patients, and up to 14 - 21 days in puerperal women). The PRL-lowering effect is dose-related both in terms of degree of effect and duration of action.</p><p>With regard to the endocrine effects of cabergoline not related to the antiprolactinaemic effect, available data from humans confirm the experimental findings in animals indicating that the test compound is endowed with a very selective action with no effect on basal secretion of other pituitary hormones or cortisol. The pharmacodynamic actions of cabergoline not correlated with the therapeutic effect only relate to blood pressure decrease. The maximal hypotensive effect of cabergoline as single dose usually occurs during the first 6 hours after drug intake and is dose-dependent both in terms of maximal decrease and frequency.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetic and metabolic profiles of cabergoline have been studied in healthy volunteers of both sexes and in female hyperprolactinaemic patients.</p><p>After oral administration of the labelled compound, radioactivity was rapidly absorbed from the gastrointestinal tract as the peak of radioactivity in plasma was between 0.5 and 4 hours.</p><p>Ten days after administration about 18% and 72% of the radioactive dose was recovered in urine and faeces, respectively. Unchanged drug in urine accounted for 2-3% of the dose.</p><p>In urine, the main metabolite identified was 6-allyl-8&beta; -carboxy-ergoline, which accounted for 4-6% of the dose. Three additional metabolites were identified in urine, which accounted overall for less than 3% of the dose. The metabolites have been found to be much less potent than cabergoline in inhibiting prolactin secretion in vitro. Cabergoline biotransformation was also studied in plasma of healthy male volunteers treated with [14C]-cabergoline: a rapid and extensive biotransformation of cabergoline was shown.</p><p>The low urinary excretion of unchanged cabergoline has been confirmed also in studies with non-radioactive product. The elimination half-life of cabergoline, estimated from urinary excretion rates, is long (63-68 hours in healthy volunteers (using a radio-immuno assay), 79-115 hours in hyperprolactinaemic patients (using a HPLC method).</p><p>On the basis of the elimination half-life, steady state conditions should be achieved after 4 weeks, as confirmed by the mean peak plasma levels of cabergoline obtained after a single dose (37 &plusmn; 8 pg/ml) and after a 4 week multiple regimen (101 &plusmn; 43 pg/ml).</p><p>In vitro experiments showed that the drug at concentrations of 0.1-10 ng/ml is 41-42% bound to plasma proteins. Food does not appear to affect absorption and disposition of cabergoline.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There were maternotoxic effects but no teratogenic effects in mice given cabergoline at doses up to 8 mg/kg/day (approximately 55 times the maximum recommended human dose) during the period of organogenesis.</p><p>A dose of 0.012 mg/kg/day (approximately 1/7 the maximum recommended human dose) during the period of organogenesis in rats caused an increase in post-implantation embryofoetal losses. These losses could be due to the prolactin inhibitory properties of cabergoline in rats. At daily doses of 0.5 mg/kg/day (approximately 19 times the maximum recommended human dose) during the period of organogenesis in the rabbit, cabergoline caused maternotoxicity characterized by a loss of body weight and decreased food consumption. Doses of 4 mg/kg/day (approximately 150 times the maximum recommended human dose) during the period of organogenesis in the rabbit caused an increased occurrence of various malformations. However, in another study in rabbits, no treatment-related malformations or embryofoetotoxicity were observed at doses up to 8 mg/kg/day (approximately 300 times the maximum recommended human dose).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-&nbsp;&nbsp; Microcrystalline cellulose</p><p>-&nbsp;&nbsp; Citric acid&nbsp;</p><p>-&nbsp;&nbsp; Magnesium stearate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>Store in the original package.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aluminum/aluminum blisters.</p><p>Pack sizes: 2 and/or 8 Tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries
Al-Kharj Road 
P.O. Box 106229
Riyadh 11666, Saudi Arabia
Tel: + (966-11) 8107023, + (966-11) 2142472
Fax: + (966-11) 2078170
e-mail: SAPV@hikma.com 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                28 July 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>